Key facts
- This page summarizes Martha Morrell's Form 4 filing for NeuroPace Inc (NPCE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 25 Feb 2025, 18:51.
Martha Morrell - 12 Feb 2024 Form 4 Insider Report for NeuroPace Inc (NPCE)
- Reporting relationship
- CHIEF MEDICAL OFFICER
- Issuer ticker
- NPCE
- Reported as of
- 12 Feb 2024
- Net transaction value
- +$1,300
- SEC form
- 4
- Accepted by SEC
- 25 Feb 2025, 18:51:01 UTC
- Prior SEC filing
- 06 Feb 2024
- Next SEC filing
- 28 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Leah Akin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Martha Morrell filed Form 4 for NeuroPace Inc (NPCE) on 25 Feb 2025.
Change
- Previous filing in this sequence was filed on 06 Feb 2024.
- Current net transaction value: +$1,300.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NPCE
transaction
Common Stock
Options Exercise
- Transaction value
- $1,300
- Shares
- +50,000
- Change %
- +45%
- Price
- $0.0260
- Shares after
- 160,327
- Date
- 12 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NPCE
transaction
Derivative
Stock Option (Rt to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -50,000
- Change %
- -26%
- Price
- $0.000000
- Shares after
- 140,449
- Date
- 12 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $0.0260
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 13,847 shares acquired pursuant to the NeuroPace, Inc. 2021 Employee Stock Purchase Plan between April 22, 2021 and June 7, 2024.
Footnote F2
1/48th of the shares subject to the option vest in equal monthly installments commencing September 19, 2020. If, at the time of the initial public offering, less than 232,371 of the shares subject to this option remain unvested, an amount of shares subject to this option shall vest and become immediately exercisable immediately prior to the offering such that a total of 232,371 shares subject to this option will be vested and immediately exercisable, subject to Dr. Morrells continued service with NeuroPace, Inc. Following such acceleration, the remaining unvested shares subject to this option will continue to vest in equal monthly installments over 48 months.